基于昆的神经皮林-1对抗剂表现出纯抗体特征,并阻断血管内皮生长因子诱导的疼痛
Sara Hestehave1, Silvia Dragoni2, Philip Fallon3
1Department of Molecular Pathobiology, College of Dentistry, New York University, New York, New York 10010, United States.
ACS pharmacology & translational science
|November 20, 2025
概括
一种新的化合物EG01449 (12h) 作为神经皮林-1 (NRP1) 抗剂,可减少疼痛信号传递. 这一发现通过向血管内皮生长因子 (VEGF) 途径,为慢性疼痛提供了一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 无感觉性疼痛影响全球许多人,目前的治疗方法具有显著的副作用.
- 现有的疼痛管理疗法受到成和器官损伤等问题的限制.
- 新的治疗目标对于开发更安全,更有效的疼痛治疗至关重要.
研究的目的:
- 设计,合成和表征EG01449 (12h),一种基于素的新型神经平素-1 (NRP1) 抗剂.
- 在血管内皮生长因子 (VEGF) 诱导的疼痛模型中评估12h的止痛作用.
- 研究12h的作用机制,重点关注其与NRP1和下游信号通路的相互作用.
主要方法:
- 基于林的化合物的合成和表征 12h.
- 利用VEGF诱导的疼痛模型来评估镇痛特性.
- 在背部根 (DRG) 感官神经元上进行电生理学记录,以测量离子通道活性.
- 进行X射线晶体学以确定12h与NRP1.1结合的结构基础.
- 评估p38基激活蛋白激酶 (MAPK) 的激活,以评估非目标效应.
主要成果:
- 化合物12h在VEGF诱导的疼痛模型中显示出镇痛作用.
- 12h通过阻断NRP1.1,在DRG神经元中抑制了VEGFA165a诱导的电流.
- 12小时减弱的机械体和冷诱导的体.
- 与其他NRP1抗剂不同,12h没有激活p38 MAPK,这表明它具有纯抑制性.
- X射线结晶学揭示了额外的键,增强了12h/NRP1复合物的稳定性.
结论:
- EG01449 (12h) 是一种强大的NRP1抗剂,具有显著的抗受体作用.
- 结构修改导致了更好的抑制药理学特征.
- NRP1对抗是一种有前途的治疗策略,用于治疗慢性疼痛.
- 准NRP1为目前的止痛药提供了一个潜在的替代品,副作用较少.
相关概念视频
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
527
Drugs Acting on Autonomic Ganglia: Blockers
1.6K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
864
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
864
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K


